

***TB VACCINES 2010 REGISTRATION CLOSES ON
WEDNESDAY, SEPTEMBER 1, 2010***

**TB Vaccines: The Second Global Forum on TB Vaccines
21-24 September 2010, Sokos Hotel Viru, Tallinn, Estonia**

A Framework for Introducing Improved TB Vaccines to the World Community

The first "Global Forum" held on June 7-8, 2001 in Geneva, Switzerland, concluded that the "driving force" for identifying improved vaccines for tuberculosis over the next ten years would be moving investigational TB vaccines into human clinical trials. The major objectives of the "Second Global Forum" are to review the progress in the TB vaccine field over the last decade and to re-frame the global agenda and timelines for introducing improved TB vaccines into practice. Using five major topics established at the first Forum, current challenges and proposed solutions will be discussed and recommendations to keep the field moving forward will be identified. This will be done through expert presentations on critical topics over two days and workshops to identify new recommendations on day three. The conference will incorporate the current goals of the Stop TB Partnership and other national and international TB initiatives, emphasizing coordination with TB diagnostics development.

This scientific conference will include international experts chairing sessions on: 1) Basic Research, 2) Applied Research, 3) Clinical Studies on TB Vaccines, 4) Manufacturing, Regulation and Vaccine Access and 5) Partnerships, Communication & Coordination.

Participants will review progress on TB vaccines over the past ten years; assess challenges; propose solutions and reframe the global agenda for TB vaccines for the next decade.

Advisory Panel

Michael Brennan (Aeras Global TB Vaccine Foundation), Ulrich Fruth (World Health Organization), Jelle Thole (TuBerculosis Vaccine Initiative), Jan Gheuens (The Bill & Melinda Gates Foundation), Stefan H.E. Kaufmann (Max Planck Institute for Infection Biology), Greg Hussey (Institute of Infectious Disease & Molecular Medicine), Christine Sizemore (National Institutes of Health), Rick O'Brien (Foundation for Innovative New Diagnostics),

Current Sponsors



TUBERCULOSIS FOUNDATION



Register on line at www.tbvaccine2010.org

Final date for abstract submissions is Monday 12 July 2010

Abstract Submissions

All attendees are invited to submit an Abstract to be considered for display at the 2010 Global TB Vaccine Conference. Abstracts will be reviewed, in advance, for relevance to the conference subject matter by an Advisory Committee Panel. Each Abstract should contain a Title, Author name(s) with Affiliations and should be no greater in length than one page, single spaced, in size 11 font.

The primary focus of this conference will be the following disciplines:

Basic Research - New findings in molecular, immunological, and pathogenesis and epidemiologic research, vaccine delivery and adjuvants.

Applied Research - Vaccine products; assay development; biomarkers; and preclinical studies.

Clinical Studies on TB Vaccines - Vaccines in clinical studies; lessons learned from trials; immunization strategies; phase II and III studies; next generation vaccines.

Manufacturing, Regulation and Vaccine Access - Pilot facilities; industrial development of TB vaccines; role of developing countries; IP issues and technology transfer; global regulation pathways; GMP assays.

Partnerships, Communication & Coordination - Role of major institutions and international organizations in TB vaccine development; coordinating new vaccine and new diagnostics studies; working in developing countries.

You will be notified via e-mail of acceptance of your Abstract for presentation as a poster at the meeting. Certain outstanding Abstract submissions may be selected to receive registration/travel stipends.

The deadline for the submission of Abstracts is 12 July 2010.

Submit an abstract on line at www.tbvaccine2010.org

Venue Information

Sokos Hotel Viru
Viru Valjak 4
10111 Tallinn, Estonia

Phone: +372 680 9300

All attendees who wish to secure overnight room accommodations at the host hotel must reserve a room through the Register Now page www.tbvaccine2010.org.



Sokos Hotel Viru

Conference Program - Tuesday, September 21

Registration

Complimentary Walking Tours

SPECIAL OPENING SESSION:

'History of TB'

Timo Ulrichs (*Koch-Mechnikov Forum*)

'Current Status of TB in the World'

Chris Dye (*World Health Organization*)

Welcome Reception with Keynote Speaker

The Honorable Hanno Pevkar, Estonian Ministry of Social Affairs

Conference Program - Wednesday, September 22

Welcome Introduction

Stop TB Task Force Presentation:

'TB Vaccines: Overview'

Michel Gréco (Stop TB Partnership Working Group)

SESSION I:

BASIC RESEARCH

Co-Chairs:

Paul-Henri Lambert (University of Geneva)

William Jacobs Jr. (Albert Einstein College of Medicine)

Presentations from:

Peter Andersen (Statens Serum Institute)

Stefan H.E. Kaufmann (Max Planck Institute for Infection Biology)

James Galagan (Boston University)

Christian Lienhardt (Stop TB Partnership) (invited)

SESSION II:

APPLIED RESEARCH

Co-Chairs:

Alexander Apt (Central Institute for TB)

Hazel Dockrell (London School of Hygiene & Tropical Medicine)

Presentations from:

Hazel Dockrell (London School of Hygiene & Tropical Medicine)

Jerrold Ellner (Boston Medical College)

Willem Hanekom (South African Tuberculosis Vaccine Initiative)

Carlos Martin (Universidad de Zaragoza)

William Jacobs Jr. (Albert Einstein College of Medicine)

Tom Ottenhoff (Leiden University Medical Center)

David Lewinsohn (Oregon Health & Science University)

SESSION III:

MANUFACTURING, REGULATION AND VACCINE ACCESS

Co-Chairs:

Pascal Mettens (GlaxoSmithKline Biologicals)

Sheldon Morris (U.S. Food and Drug Administration)

Presentations from:

Gerard Cunningham (The Bill & Melinda Gates Foundation)

Daniel Chin (The Bill & Melinda Gates Foundation)

Roland Dobbelaer (TuBerculosis Vaccine Initiative)

Lew Barker (Aeras Global TB Vaccine Foundation)

Poster Viewing

Conference Dinner

Keynote Presentation:

Peter Small (The Bill & Melinda Gates Foundation)

Conference Program - Thursday, September 23

SESSION IV:

CLINICAL STUDIES ON TB VACCINES

Co-Chairs:

Harriet Mayanja-Kizza (Kampala University)

Greg Hussey (University of Cape Town)

Presentations from:

Hassan Mahomed (South African Tuberculosis Vaccine Initiative)

J. Bruce McClain (Aeras Global TB Vaccine Foundation)

Helen McShane (Oxford University)

Jerald Sadoff (Crucell)

Søren Hoff (Statens Serum Institut)

Opokua Ofori-Anyinam (GlaxoSmithKline Biologicals)

Leander Grode (Vakzine Projekt Management)

Ford von Reyn (Dartmouth-Hitchcock Medical Center)

Luis Ruiz (Archivel)

Zhou Xing (McMaster University)

SESSION V:

PARTNERSHIPS, COMMUNICATION & ADVOCACY

Co-Chairs:

Jelle Thole (TuBerculosis Vaccine Initiative)

Christine Sizemore (National Institutes of Health)

Presentations from:

Robert Nakibumba (Community Representative to the Stop TB Partnership Working Group on New TB Vaccines)

Charles Mgone (European and Developing Countries Clinical Trials Partnership)

Rick O'Brien (Foundation for Innovative New Diagnostics)

Jennifer Woolley (Aeras Global TB Vaccine Foundation)

Joris Vandeputte (TuBerculosis Vaccine Initiative)

Claire Wingfield (Treatment Action Group)

Poster Viewing

Free Evening

SPECIALS ISSUES MEETING:

'Clinical endpoints Sponsored by the Taskforce on Clinical Research Issues in TB Vaccine Development'

Hassan Mahomed (South African Tuberculosis Vaccine Initiative)

Conference Program - Friday, September 24

WORKSHOPS:

Session I: Basic Research

Chair:

Patrick Brennan (Colorado State University)

Session II: Applied Research

Chair:

Douglas Young (Imperial College)

Session III: Manufacturing, Regulation & Vaccine Access

Chair:

Jerald Sadoff (Crucell)

Session IV: Clinical Studies on TB Vaccines

Chair:

Bernard Fourie (Medicine in Need)

Session V: Partnerships, Communication & Advocacy

Chair:

Christine Sizemore (National Institutes of Health)

Wrap-Up Session

Conference concludes around 3:00 pm

Optional Tour of Kadroing Palace & Kumu Art Museum

See more detailed agenda on line at www.tbvaccine2010.org

General Information

REGISTRATION

Attendees should register for *TB Vaccines: A Second Global Forum* by completing the on line registration form at www.tbvaccines2010.org. The cost for conference registration is \$475 (USD). This includes all scheduled meal functions. The final date for registration is 1 September 2010.

VENUE AND ACCOMMODATIONS

The venue for the conference is the Sokos Hotel Viru in Tallinn, Estonia.

Special discounted accommodation rates have been negotiated. To receive these rates and guarantee your reservation you must book your accommodations through the on line registration at www.tbvaccine2010.org.

Hotel Cancellation & Refund Policy

- All registrations should be paid in full by 1 September 2010.
- 100% refundable* up to 1 July 2010.
- 50% refundable* between 1 July - 15 August 2010.
- Non-refundable after 15 August 2010.
* Less \$50.00 administrative costs

PUBLICATION

A flash drive of the final program and abstracts of all presentations will be distributed to attendees when they register at the conference.

AIR TRAVEL

Signature Travel, Inc. is the official travel agency for this conference and has secured discounted airfares of 10-15% for our attendees on Lufthansa Airlines and their Star Alliance partners. Book as soon as possible to take advantage of the fares which give you the greatest discounts. Once you have selected your flights, you will receive an itinerary reflecting the discounts for your approval. Upon your approval, it will then be ticketed.

Please note that you may achieve significant reduction in air travel expenditures by choosing to fly on either Saturday or Sunday. Therefore, please check different date options if your schedule allows for flexibility of travel to and from the meeting.

For questions regarding air travel you may email info@signaturetv.com.

SPECIAL NOTICE

Special notice for prospective attendees that wish to apply for a registration/travel stipend to attend the conference.

If you wish to be considered for a registration/travel stipend to attend the conference you must submit an abstract on line at www.tbvaccine2010.org by 12 July 2010. Also, please notify Michael Brennan at mbrennan@aeras.org and Jeannine Tilman at jtilman@aeras.org with a written request for a stipend and include your name, affiliation and contact information.

1 SEPTEMBER 2010

REGISTRATION CLOSES - ALL PAYMENTS ARE DUE IN FULL